Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Express Scripts
Moodys
Harvard Business School
Dow

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR AGGRASTAT


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Aggrastat

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00251576 ↗ Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180) Completed Merck Sharp & Dohme Corp. Phase 3 1999-11-01 A-Phase: Evaluating patients with chest pain who are receiving approved drugs, to estimate the effectiveness of one type of blood thinner as compared to another type of blood thinner. Z-Phase: To evaluate early treatment of patients with long term chest pain (using an approved drug for 30 days, followed by an increased dose of the drug) as compared to patients (treated with diet and 4 months placebo followed by diet and approved drug) in patients who have experienced acute chest pain or heart attack.
NCT00300833 ↗ Treating Acute MI Patients With Aggrastat on Their Way to Hospital Unknown status The Baruch Padeh Medical Center, Poriya Phase 4 2006-01-01 Treating an AMI patient with ST elevation with Aggrastat in the ambulance on his or her way to the hospital.
NCT00383136 ↗ FATA: Randomized Study on Facilitated Angioplasty With Tirofiban or Abciximab Completed University of Bologna Phase 4 2003-06-01 The elective("standard of care") treatment of ST - elevation acute myocardial infarction (STEMI) currently consists of primary angioplasty with stent implantation during administration of Abciximab, a inhibitor of GP IIb/IIIa platelet receptor. Tirofiban is another potent inhibitor of GP IIb/IIIa platelet receptor with an efficacy on platelet aggregation inhibition equal to or greater than Abciximab if a high dose bolus is used, i.e. 25 microg/kg, (platelet aggregation inhibition > 90% 15 minutes after infusion). It can therefore be hypothesized that this drug can improve the results of primary angioplasty to the same extent as Abciximab. The aim of this study is to compare the efficacy, in terms of myocardial reperfusion indices, of Abciximab and high dose of Tirofiban in primary angioplasty for STEMI, both in the case of treatment before transfer and of treatment in the catheterization laboratory during the procedure. The reference hypothesis for the study objective is the equivalence or the non-inferiority of Tirofiban with respect to Abciximab.
NCT00566891 ↗ Safety of High-dose Tirofiban During Coronary Angioplasty Completed S. Anna Hospital Phase 4 2007-12-01 This single-centre study is intended to retrospectively check the safety of high-dose bolus of tirofiban in patients who underwent percutaneous angioplasty.
NCT01109134 ↗ Tirofiban Intracoronary Bolus-only Versus Intravenous Bolus Plus Infusion in STEMI Patients Completed The Society of Cardiac Health Protection Phase 3 2008-09-01 The aim of this randomized trial is to compare the efficacy of high dose tirofiban administered as either an intracoronary bolus alone or as an intravenous bolus followed by a maintenance infusion with respect to microvascular perfusion and long term left ventricular infarct size, volumes and function.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Aggrastat

Condition Name

Condition Name for Aggrastat
Intervention Trials
Acute Myocardial Infarction 3
Coronary Artery Disease 3
Myocardial Infarction 2
Acute Coronary Syndromes 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Aggrastat
Intervention Trials
Myocardial Infarction 7
Infarction 7
Myocardial Ischemia 3
Coronary Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Aggrastat

Trials by Country

Trials by Country for Aggrastat
Location Trials
United States 10
Italy 8
China 1
Switzerland 1
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Aggrastat
Location Trials
Iowa 2
Florida 2
Virginia 1
Tennessee 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Aggrastat

Clinical Trial Phase

Clinical Trial Phase for Aggrastat
Clinical Trial Phase Trials
Phase 4 5
Phase 3 4
Phase 2 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Aggrastat
Clinical Trial Phase Trials
Completed 9
Unknown status 2
Withdrawn 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Aggrastat

Sponsor Name

Sponsor Name for Aggrastat
Sponsor Trials
Medicure 3
SCRI Development Innovations, LLC 2
David Hasan 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Aggrastat
Sponsor Trials
Other 12
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Baxter
Boehringer Ingelheim
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.